Your browser doesn't support javascript.
loading
Influence of rapid COVID-19 vaccine development on vaccine hesitancy.
Rosenthal, Sonny; Cummings, Christopher L.
Afiliação
  • Rosenthal S; Wee Kim Wee School of Communication and Information, Nanyang Technological University, Singapore. Electronic address: sonnyrosenthal@ntu.edu.sg.
  • Cummings CL; United States Army Corps of Engineers Engineer Research and Development Center (contractor), North Carolina State University, Iowa State University, United States.
Vaccine ; 39(52): 7625-7632, 2021 12 20.
Article em En | MEDLINE | ID: mdl-34802786
ABSTRACT

INTRODUCTION:

In the race to deploy vaccines to prevent COVID-19, there is a need to understand factors influencing vaccine hesitancy. Secondary risk theory is a useful framework to explain this, accounting for concerns about vaccine efficacy and safety.

METHODS:

During the first week of July, 2020, participants (N = 216) evaluated one of three different hypothetical vaccine scenarios describing an FDA-approved vaccine becoming available "next week," "in one year," or "in two years." Dependent variables were perceived vaccine efficacy, self-efficacy, perceived vaccine risk, and vaccination willingness. Covariates included vaccine conspiracy beliefs, science pessimism, media dependency, and perceived COVID-19 risk. Data analysis employed multiple analysis of covariance (MANCOVA).

RESULTS:

Perceived vaccine efficacy was lowest for the next-week vaccine (η2p = .045). Self-efficacy was higher for the two-year vaccine than the next-week vaccine (η2p = .029). Perceived vaccine risk was higher for the next-week vaccine than for the one-year vaccine (η2p = .032). Vaccination willingness did not differ among experimental treatments. In addition, vaccine conspiracy beliefs were negatively related to perceived vaccine efficacy (η2p = .142), self-efficacy (η2p = .031), and vaccination willingness (η2p = .143) and positively related to perceived vaccine risk (η2p = .216).

CONCLUSIONS:

The rapid development of the COVID-19 vaccine may have heightened public concerns over efficacy, availability, and safety. However, the current findings showed a general willingness to take even the most rapidly developed vaccine. Nonetheless, there remains a need to communicate publicly and transparently about vaccine efficacy and safety and work to reduce vaccine conspiracy beliefs.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article